08:50 AM EST, 11/06/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday its eloralintide, an investigational once-weekly, selective amylin receptor agonist, demonstrated superior mean weight reductions from 9.5% to 20.1% in a phase 2 trial.

The trial featured 263 adults with obesity or who are overweight with at least one obesity-related comorbidity and without type 2 diabetes, the company said.

"These data show that eloralintide, a selective amylin receptor agonist, offers the potential for strong efficacy with improved tolerability and could serve as an alternative to incretin therapies," said Kenneth Custer, president of Lilly Cardiometabolic Health.